Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Shaji K Kumar
Division of Hematology, Mayo Clinic, Minnesota
The research of Shaji Kumar, M.D., focuses on development of novel drugs for treatment of myeloma. Dr Kumar’s research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.
Dr Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes. His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.
Dr Shaji Kumar discloses: Research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.
Dr Rahma Warsame
Division of Hematology, Mayo Clinic, Minnesota
The research of Rahma Warsame, M.D., is focused on amyloidosis and multiple myeloma. Dr Warsame is interested in investigating existing health care delivery systems to improve patient-reported outcomes and quality of life. She is also working on incorporating patient perspectives into clinical practice and determining its effect on clinical outcomes.
Dr Rahma Warsame discloses: No known competing financial interests or personal relationships that could have appeared to influence the content of this activity.
